Please try another search
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. Its product includes Aeson, an active implantable medical device intended to replace the ventricles of the native heart in patients suffering from advanced heart failure. The company was incorporated in 2008 and is headquartered in Vélizy-Villacoublay, France.
Name | Age | Since | Title |
---|---|---|---|
Alain Carpentier | - | 2010 | Honorary President |
Stephane Piat | 50 | 2016 | CEO & Director |
Pierre Bastid | 67 | 2018 | Independent Director |
Antonino Ligresti | 83 | 2016 | Independent Director |
Karl Hennessee | - | 2019 | Representative Director |
Michael Mack | 74 | 2017 | Independent Director |
Alexandre Conroy | 59 | 2022 | Chairman of the Board |
Mark Slaughter | - | - | Member of the Scientific Committee |
Jean-Luc Lemercier | 66 | 2017 | Independent Director |
Gunther Laufer | - | - | Member of the Scientific Committee |
Friedrich-Wilhelm Mohr | - | - | Member of the Scientific Committee |
Paul Mohacsi | - | - | Member of the Scientific Committee |
Edoardo Gronda | - | - | Member of the Scientific Committee |
John B. Hernandez | 57 | 2021 | Independent Director |
André C. Muller | 60 | 2020 | Independent Director |
David Coti | 41 | 2021 | Director |
Florent Battistella | 63 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review